Bayer AG
XETRA:BAYN
Bayer AG
XETRA:BAYN
Price:
26.97 EUR
-1.39%
Market Closed
Updated:
Apr 25, 2024
Bayer AG
Capital Expenditures
Last
Value
3-Years CAGR
5-Years CAGR
|
Bayer AG
Capital Expenditures Peer Comparison
Comparables:
ATAI
MRK
93M1
DMP
PSG
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bayer AG
XETRA:BAYN
|
Capital Expenditures
-€2.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Capital Expenditures
-$590k
|
CAGR 3-Years
-114%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck KGaA
XETRA:MRK
|
Capital Expenditures
-€2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-15%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Capital Expenditures
-€5.6k
|
CAGR 3-Years
53%
|
CAGR 5-Years
80%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Capital Expenditures
-€41.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Capital Expenditures
-€787k
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
See Also
What is Bayer AG's Capital Expenditures?
Capital Expenditures
-2.8B
EUR
-2.8B
EUR
Based on the financial report for Dec 31, 2023, Bayer AG's Capital Expenditures amounts to -2.8B EUR.
What is Bayer AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-2%
-2%
Over the last year, the Capital Expenditures growth was 7%. The average annual Capital Expenditures growth rates for Bayer AG have been -4% over the past three years , -1% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet
